Taking Abortion to the Polls: What To Expect in Ohio

By Joelle Boxer Dobbs “return[ed]” the authority to regulate abortion to “the people and their elected representatives.” The people of

FDA: New Draft Guidance on Communication of Unapproved Uses of Approved or Cleared Medical Products

On October 23, the U.S. Food and Drug Administration (FDA) issued draft guidance, Communication from Firms to Health Care Providers

By Kayum Ahmed, Julia Bleckner, and Kyle Knight In mid-May, the World Health Organization officially declared the “emergency” phase of

By Adithi Iyer In my last piece, I discussed the hypothetical successor of 23andme — a tissue-based direct-to-consumer testing service

On October 10, 2023, the U.S. Food and Drug Administration (FDA) issued a public warning regarding the potential health risks

By: Carrie Chapman, Stephanie Altman, and Nadeen Israel This blog is part of our Working Better Together series and was recorded

By Vincent Joralemon A $70 million deal struck between a venture capital firm and a prominent psychedelic advocacy organization suggests

By Roojin Habibi, Timothy Fish Hodgson, and Alicia Ely Yamin Today, as the world transitions from living in the grips

By Camila Gianella Between August and mid-October 2023, media reports documented a string of tragedies: six Peruvian girls between the

By Hannah Rahim After the Supreme Court eliminated the constitutionally protected right to abortion in Dobbs v. Jackson Women’s Health